Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
J Public Health Manag Pract ; 28(Suppl 6): S355-S358, 2022.
Article in English | MEDLINE | ID: mdl-36194806

ABSTRACT

The Martinsburg Initiative (TMI) is a community-based model developed in Martinsburg, West Virginia, that implements a comprehensive approach to adverse childhood experiences and substance use prevention and mitigation by leveraging partnerships in public health and health care, public safety, and education. TMI receives coordinated federal funding and technical assistance from the Centers for Disease Control and Prevention, the Washington-Baltimore High Intensity Drug Trafficking Agency, and the National Association of County and City Health Officials to integrate evidence-based and promising strategies. It advances such strategies by translating them for implementation within the community, evaluating the reach and potential impact of the model, and by engaging key stakeholders. Preliminary results describing program reach and short-term outcomes collected for a subset of the interventions during implementation are presented. The model uses touchpoints across multiple community sectors in the city of Martinsburg to break the cycle of trauma and substance use across the life span.


Subject(s)
Public Health , Substance-Related Disorders , Centers for Disease Control and Prevention, U.S. , Delivery of Health Care/methods , Humans , Schools , Substance-Related Disorders/epidemiology , Substance-Related Disorders/prevention & control , United States
2.
J Behav Health Serv Res ; 51(1): 114-122, 2024 Jan.
Article in English | MEDLINE | ID: mdl-37414999

ABSTRACT

Despite the effectiveness of medication-assisted treatment (MAT), adults receiving MAT experience opioid cravings and engage in non-opioid illicit substance use that increases the risk of relapse and overdose. The current study examines whether negative urgency, defined as the tendency to act impulsively in response to intense negative emotion, is a risk factor for opioid cravings and non-opioid illicit substance use. Fifty-eight adults (predominately White cis-gender females) receiving MAT (with buprenorphine or methadone) were recruited from online substance use forums and asked to complete self-report questionnaires on negative urgency (UPPS-P Impulsive Behavior Scale), past 3-month opioid cravings (ASSIST-Alcohol, Smoking, and Substance Involvement Screening Test), and non-opioid illicit substance use (e.g., amphetamines, cocaine, benzodiazepines). Results revealed that negative urgency was associated with past 3-month opioid cravings, as well as past month illicit stimulant use (not benzodiazepine use). These results may indicate that individuals high in negative urgency would benefit from receiving extra intervention during MAT.


Subject(s)
Buprenorphine , Opioid-Related Disorders , Adult , Female , Humans , Methadone/therapeutic use , Buprenorphine/therapeutic use , Analgesics, Opioid/therapeutic use , Opioid-Related Disorders/drug therapy , Opioid-Related Disorders/epidemiology , Opioid-Related Disorders/psychology , Craving , Opiate Substitution Treatment/methods
3.
PLoS One ; 17(12): e0269509, 2022.
Article in English | MEDLINE | ID: mdl-36584000

ABSTRACT

Opioid overdoses within the United States continue to rise and have been negatively impacting the social and economic status of the country. In order to effectively allocate resources and identify policy solutions to reduce the number of overdoses, it is important to understand the geographical differences in opioid overdose rates and their causes. In this study, we utilized data on emergency department opioid overdose (EDOOD) visits to explore the county-level spatio-temporal distribution of opioid overdose rates within the state of Virginia and their association with aggregate socio-ecological factors. The analyses were performed using a combination of techniques including Moran's I and multilevel modeling. Using data from 2016-2021, we found that Virginia counties had notable differences in their EDOOD visit rates with significant neighborhood-level associations: many counties in the southwestern region were consistently identified as the hotspots (areas with a higher concentration of EDOOD visits) whereas many counties in the northern region were consistently identified as the coldspots (areas with a lower concentration of EDOOD visits). In most Virginia counties, EDOOD visit rates declined from 2017 to 2018. In more recent years (since 2019), the visit rates showed an increasing trend. The multilevel modeling revealed that the change in clinical care factors (i.e., access to care and quality of care) and socio-economic factors (i.e., levels of education, employment, income, family and social support, and community safety) were significantly associated with the change in the EDOOD visit rates. The findings from this study have the potential to assist policymakers in proper resource planning thereby improving health outcomes.


Subject(s)
Drug Overdose , Opiate Overdose , Humans , United States , Analgesics, Opioid , Emergency Service, Hospital , Drug Overdose/epidemiology , Virginia/epidemiology
4.
Clin Pediatr (Phila) ; 56(7): 605-615, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28503996

ABSTRACT

The safety and efficacy of a 2-dose series for the human papillomavirus vaccines rather than a 3-dose series in older children has not been well defined. This article reviews the literature summarizing the use of all 3 HPV vaccines (2vHPV, 4vHPV, 9vHPV) as a 2-dose series for females and 4vHPV and 9vHPV for males younger than 15 years. Six prospective trials evaluating immunogenicity of a 2-dose series of 2vHPV and/or 4vHPV, as well as an ongoing prospective clinical trial for 9vHPV, are discussed. The 2-dose series with Gardasil 9® in both males and females ages 9 to 14 years appears to be the most widely accepted recommendation. The exact time schedule between the 2 vaccines varies among studies, but it seems that they should be separated by 6 to 12 months. Federal and world-wide organizations' (ie, Centers for Disease Control and Prevention, Food and Drug Administration, and World Health Organization) opinions and recommendations on the appropriate scheduling of the vaccines are also highlighted.


Subject(s)
Immunization/methods , Papillomavirus Infections/prevention & control , Papillomavirus Vaccines/therapeutic use , Child , Humans , Immunization Schedule
SELECTION OF CITATIONS
SEARCH DETAIL